Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.62 |
| ▸ | ECE1 | P42892 | 5/20 | 0.61 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788017 | 0.98 | ERAP2 (0.64) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL31004373 | 0.96 | ERAP2 (0.61) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL30416193 | 0.96 | ECE1 (0.64) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL30788023 | 0.94 | ERAP2 (0.63) | GHSRECE1ERAP2IL1RNERAP1 | |
| SCHEMBL31583852 | 0.93 | ERAP2 (0.63) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL31720495 | 0.93 | ERAP2 (0.63) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL29378588 | 0.93 | ERAP2 (0.63) | GHSRECE1ERAP2ACEIL1RN | |
| SCHEMBL30929767 | 0.93 | ERAP2 (0.58) | GHSRECE1ERAP2IL1RNERAP1 | |
| SCHEMBL30788022 | 0.92 | ERAP2 (0.59) | GHSRECE1ERAP2IL1RNERAP1 | |
| SCHEMBL31232500 | 0.92 | ERAP2 (0.63) | GHSRECE1ERAP2ACEIL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332758-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH | 2022-10-20 | — | — | US | disclosed |
| EP-4028038-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Board of Regents, The University of Texas System (US) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332758-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, IAPP, BACE1 | GHSR 340/4885ECE1 2560/4885ERAP2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.